Summary
Synopsis
Betaxolol is a lipophilic β-adrenoceptor antagonist relatively selective for β1-adrenoceptors with only weak β2-blocking activity. Used topically in glaucoma and ocular hypertension, betaxolol 0.5% solution produces a reduction in intraocular pressure of between 13 and 30%, an effect comparable with that of ocular timolol. It may usefully be combined with other types of anti-glaucoma agents. The most notable feature of its adverse effect profile is transient local stinging or irritation, occurring in 25 to 40% of patients. Following ocular administration, betaxolol appears to be largely devoid of adverse bronchopulmonary or cardiac effects, in comparison with nonselective ocular β-adrenoceptor antagonists, which may be more likely to exert systemic effects. Betaxolol has negligible local anaesthetic activity, so that corneal desensitisation does not occur with its use. Thus, betaxolol is an alternative therapeutic option available to the physician for the management of chronic open-angle glaucoma and ocular hypertension. Its apparently lower propensity to affect the cardiopulmonary system represents a significant advantage over other ocular β-adreno-ceptor antagonists.
Pharmacodynamic Properties
Betaxolol is a lipid-soluble (lipophilic) β-adrenoceptor antagonist which is relatively cardioselective, with no intrinsic sympathomimetic activity and little or no membrane stabilising activity. In common with other ocular β-adrenoceptor antagonists, the mechanism of the reduction in intraocular pressure observed with betaxolol is generally considered to be decreased production of aqueous humour by the ciliary body, with no apparent effect on aqueous outflow. The precise mechanism of this effect remains to be elucidated. Retinal and ciliary perfusion pressures in patients have been reported to be unaltered by betaxolol treatment. Betaxolol 0.5% was less toxic to regenerating corneal epithelium in rabbits than was timolol 0.5% or levobunolol 0.5%. Similarly, corneal healing rates were faster with betaxolol (and levobunolol) than with timolol.
Although ocularly administered betaxolol may be absorbed from the nasopharyngeal and conjunctival mucosa into the systemic circulation, betaxolol appears to possess minimal systemic β-blocking activity — approximately 5% that of timolol in 1 radioreceptor assay in rabbits. Ocular betaxolol also failed to antagonise the isoprenaline-induced increase in heart rate in monkeys, an index of systemic β-blockade.
Betaxolol appears to have less propensity for adverse effects on pulmonary function than nonselective ocular β-adrenoceptor antagonists. In studies in patients with respiratory disease or timolol-induced bronchoconstriction, betaxolol has not had any effect on FEV1, forced vital capacity, or relative forced expiratory volume. However, in an investigation in 85 patients followed for up to 2 years, symptomatic pulmonary obstruction was apparent in 5 patients after 1 to 554 days’ betaxolol treatment. All patients had glaucoma and chronic obstructive pulmonary disease, asthma, or timolol-induced bronchoconstriction at baseline. In 1 study, no statistically significant difference was apparent between betaxolol and placebo in the histamine concentration necessary to produce a 15 to 20% reduction in FEV1.
Despite its cardioselectivity, betaxolol has had minimal effects on resting or exercise heart rate, blood pressure or double product, after ocular administration, in several placebo-controlled studies. This is in contrast to timolol, which effects significant reductions in these parameters. In 1 study in healthy volunteers, the incidence of CNS effects, including insomnia, depression, hypochondriasis and hysteria, tended to be less with betaxolol than with timolol. In 2 further studies, 16 of 18, and 5 of 7 patients experiencing CNS effects while receiving timolol improved after betaxolol treatment.
Pharmacokinetic Properties
There are no published data detailing the pharmacokinetic properties of betaxolol following ocular administration in humans; such information is important to assess the extent of systemic availability.
The bioavailability of oral betaxolol is 80 to 90% - it does not undergo extensive first pass metabolism. Excretion is mainly via O-dealkylation followed by aliphatic hydroxylation, yielding 2 major inactive metabolites. Betaxolol and its metabolites are excreted renally with an elimination half-life of between 14 and 22 hours, which is prolonged in neonates and the elderly. Total body clearance does not appear to be affected by liver disease but is reduced in patients with severe renal failure.
Therapeutic Trials
In comparisons with placebo, betaxolol has proven superior in reducing intraocular pressure. Mean reductions have ranged between 13 and 27% with betaxolol compared with about 2 to 13% with placebo. Trials comparing betaxolol with timolol reported reductions in intraocular pressure at the end of 6 months’ treatment of between 26 and 36% with betaxolol, and between 29 and 37% with timolol. These 3 trials involved a total of 101 patients.
In a noncomparative trial a reduction of intraocular pressure was obtained within several hours of instillation of betaxolol 0.25%, was maximal at 2 weeks, at 30 to 35%, and was sustained for the duration of the study ( 1 year). In a second noncomparative trial, patients previously administered pilocarpine showed a nonsignificant reduction in intraocular pressure of 8.4% following substitution with betaxolol; in newly diagnosed patients, mean diurnal intraocular pressure was significantly reduced with betaxolol by 17%. In 17 of 20 patients with open-angle glaucoma or ocular hypertension receiving betaxolol 0.5% alone (n=15) or in combination with pilocarpine (n=5), who had been treated with timolol, an additional mean reduction in intraocular pressure of 2.4mm Hg was apparent after 2 weeks, and was maintained for the 12 weeks of study. In specific investigations of combination use, betaxolol therapy resulted in small incremental reductions in intraocular pressure over those obtained with other monotherapies.
After 2 weeks’ treatment with dipivefrine 0.1% alone, intraocular pressure was reduced by 12%, and addition of betaxolol resulted in a total reduction of 15% at 4 weeks. Betaxolol 0.5% twice daily added to oral acetazolamide resulted in an incremental reduction in outflow pressure (intraocular pressure minus an episcleral venous pressure assumed to be 10mm Hg) of 17.6%. With acetazolamide alone the reduction was 42.5%. With betaxolol alone the reduction was 27.3% below baseline, decreased by an additional 35.1% with acetazolamide.
Adverse Effects
The most frequent adverse effect of topical betaxolol treatment is transient local irritation, which occurs in 25 to 40% of patients. A double-blind comparison indicated a higher incidence of ocular symptoms with betaxolol (89%), than with timolol (48%). Ocular symptoms reported include burning, stinging or irritation, pruritus, hyphaemia, vitreous separation and blurred vision. As a cardioselective agent, betaxolol is less likely to be associated with adverse respiratory effects than nonselective β-adrenoceptor antagonists. While adverse respiratory effects have been observed in a small number of patients with underlying respiratory disease followed for up to 2 years on betaxolol, their relationship to treatment is uncertain. Of a total of 56 spontaneous reports of adverse drug experience attributed to betaxolol during its first year of marketing in the US, postmarketing surveillance identified 11 cases of asthma, 8 requiring hospitalisation.
During a clinical trial in 101 patients treated with betaxolol for up to 2 years, cardiac arrhythmia and shortness of breath occurred in 1 patient and bundle branch block in a second. There are case reports describing myocardial infarction, sinus arrest, and congestive heart failure in association with ocular betaxolol. Of the 56 spontaneous reports mentioned above, there were 4 instances of bradycardia, 1 with syncope, and 1 of cardiac arrhythmia. Other adverse effects reported in association with ocular betaxolol include depression, disorientation, vertigo and sleepwalking; and rhinitis, dysuria, alopecia, and prolonged prothrombin time.
Dosage and Administration
The recommended dosage of ocular betaxolol in glaucoma or ocular hypertension is one drop of 0.5% solution in each eye twice daily.
Similar content being viewed by others
References
Allen RC, Epstein DL. Additive effect of betaxolol and epinephrine in primary open angle glaucoma. Archives of Ophthalmology 104: 1178–1184, 1986
Allen RC, Hertzmark E, Walker AM, Epstein DL. A doublemasked comparison of betaxolol vs timolol in the treatment of open-angle glaucoma. American Journal of Ophthalmology 101: 535–541, 1986
Atkins JM, Pugh Jr BR, Timewell RM. Cardiovascular effects of topical beta-blockers during exercise. American Journal of Ophthalmology 99: 173–175, 1985
Ball S. Congestive heart failure from betaxolol: ocular. Archives of Ophthalmology 105(3): 320, 1987
Balnave K, Neill JD, Russell JD, et al. Observations on the efficacy and pharmacokinetics of betaxolol (SL75212), a cardio-selective β-adrenoceptor blocking drug. British Journal of Clinical Pharmacology 11: 171, 1981
Bartsch W, Dietmann K, Leinert H, Sponer G. Cardiac action of carazolol and methypranol in comparison with other β-receptor blockers. Arzneimittel-Forschung 27: 1022–1026, 1977
Beresford R, Heel RC. Betaxolol: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension. Drugs 31: 6–28, 1986
Berrospi AR, Leibowitz HM. Betaxolol: a new β-adrenergic blocking agent for treatment of glaucoma. Archives of Ophthalmology 100: 943–946, 1982
Berry Jr DP, Van Buskirk EM, Shields MB. Betaxolol and timolol: a comparison of efficacy and side effects. Archives of Ophthalmology 102: 42–45, 1984
Bianchetti G, Gomeni R, Kilborn J, Morselli P, et al. Blood concentrations and pharmacodynamic effect of SL 75212, a new beta-adrenoceptor antagonist, after oral and intravenous administration. British Journal of Clinical Pharmacology 8: 403P-404P, 1979
Bianchetti G, Padovani P, Thiercelin J, Thenot J, Morselli P. Pharmacokinetic studies of betaxolol — evaluation of the effects of age, hypertension, presence of food, and concomitant administration of hydrochlorothiazide on the disposition of the drug. In Morselli et al. (Eds) LERS Monograph Series, Vol. 1, pp. 123–131, Raven Press, New York, 1983
Bleckmann H, Dorow P. Betaxolol vs placebo in ten patients with glaucoma and reactive airway disease. New Trends in Ophthalmology 2: 114–123, 1987
Bloom E, Richmond C, Alvarado J, Polansky J. Betaxolol vs timolol: plasma radio-receptor assays to evaluate systemic complications of beta blocker therapy for glaucoma. Investigative Ophthalmology and Visual Science 26 (Suppl): 125–129, 1986
Boudot J, Cavero I, Fenard S, Lefèvre-Borg F, et al. Preliminary studies on SL 75212, a new potent cardioselective beta-adrenoceptor antagonist. British Journal of Pharmacology 66: 445P, 1979
Boutroy M, Vert P, Bianchetti G, Morselli P. Betaxolol: pharmacokinetics and pharmacodynamic effects of a new cardioselective beta-blocker in pregnant women. Abstract no. 565. II World Conference on Clinical Pharmacology and Therapeutics, Washington DC, July 31–August 5, 1983
Brogliatti B, Rolle T, Franzone M. Effects of topical betaxolol on ocular hypertensive or glaucomatous eyes. New Trends in Ophthalmology 2: 87–94, 1987
Brooks AMV, Burdon JGW, Gillies WE. The significance of reactions to betaxolol reported by patients. Australian and New Zealand Journal of Ophthalmology 17: 353–355, 1989
Brooks AMV, Gillies WE, West RH. Betaxolol eye drops as a safe medication to lower intraocular pressure. Australian and New Zealand Journal of Ophthalmology 15: 125–129, 1987
Caldwell DR, Salisbury CR, Guzek JP. Effects of topical betaxolol in ocular hypertensive patients. Archives of Ophthalmology 102: 539–540, 1984
Cavero I, Lefèvre-Borg F. Antihypertensive activity of betaxolol in conscious spontaneously hypertensive rats. British Journal of Pharmacology 78 (Suppl.): 28P, 1983a
Cavero I, Lefèvre-Borg F. Studies on the mechanism of the anti-hypertensive action of betaxolol, a beta 1 adrenoceptor antagonist, in spontaneously hypertensive rats. Ricerca Scientifica ed Educazione Permanente (Suppl. 33), 1983b
Cervantes R, Hernandez y Hernandez H. Pulmonary and heart rate changes associated with nonselective beta-blocker glaucoma therapy. Journal of Toxicology — Cutaneous and Ocular Toxicology 5(3): 185–193, 1986
Chamberlain TJ. Myocardial infarction after ophthalmic betaxolol. New England Journal of Medicine 321: 1342, 1989
Clark JB, Brooks AMV, Harper CA, Mantzioros N, Gillies WE. A comparison of the efficacy of betaxolol and timolol in ocular hypertension with or without adrenaline. Australian and New Zealand Journal of Ophthalmology 17(2): 173–177, 1989
Cohn JB. A comparative study of the central nervous system effects of betaxolol vs timolol. Archives of Ophthalmology 107: 633–634, 1989
Dausch D, Brewitt H, Edelhoff R. Metipranolol eye drops: clinical suitability in the treatment of chronic open angle glaucoma. In Merté (Ed.) Metipranolo, pp. 132–147, Springer-Verlag, Wien,New York, 1983
Davis B, Turner P. The spectrofluorimetric estimation and buccal absorption of SL 75212, a novel beta-adrenoceptor antagonist. British Journal of Clinical Pharmacology 8: 405P, 1979
DeSantis L, Polansky JR, Bruce L. Relative differences in beta receptor activity between the cardioselective beta blocker, betaxolol, and nonselective beta blockers. Proceedings of the XXVth International Congress of Ophthalmology, Rome, pp. 1501–1505, May 4–10, 1986, Khugler & Ghedini, Amsterdam, 1987
de Vries J, van de Merwe SA, de Heer LJ. From timolol to betaxolol. Correspondence. Archives of Ophthalmology 107: 634, 1989
Dickstein K. Comparison of the effect of timolol versus betaxolol ophthalmic on cardiopulmonary exercise performance in healthy volunteers (summary). Survey of Ophthalmology 33 (Suppl.): 457–458, 1989
Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, et al. The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects. American Review of Respiratory Disease 133: 264–268, 1986
Feghali JG, Kaufman PL. Decreased intraocular pressure in the hypertensive human eye with betaxolol, a β1 -adrenergic antagonist. American Journal of Ophthalmology 100: 777–782, 1985
Ferrandes B, Durand A, André-Fraisse J, Thénot J, Hermann P. Pharmacokinetics and metabolism of betaxolol in various animal species and man. In Morselli et al. (Eds) LERS Monograph Series, Vol. 1, pp. 51–64, Raven Press, New York, 1983
Fraunfelder FT, Meyer SM, Menacker SJ. Alopecia possibly secondary to topical ophthalmic β-blockers. Correspondence. Journal of the American Medical Association 263: 1493–1494, 1990
Ganansia J, Bianchetti G, Bouchet JL, Allen J, Morselli P. Protein binding of betaxolol in healthy volunteers and in patients with renal or hepatic disease. In Aiache and Hirtz (Eds) Proceedings of the 2nd European Congress of Biopharmaceutics and Pharmacokinetics, pp. 440–447, Vol. III, Clinical Pharmacokinetics, 24–27 April, Salamanca, Spain, 1984
Gaul GR, Will NJ, Brubaker RF. Comparison of a noncardioselective β-adrenoceptor blocker and a cardioselective blocker in reducing aqueous flow in humans. Archives of Ophthalmology 107: 1308–1311, 1989
Gillet G, Bianchetti G, Ferrandes B, Morselli P. Kinetics of the distribution of betaxolol and metoprolol in various tissues in the rat. In Aiache and Hirtz (Eds) Proceedings of 2nd European Congress of Biopharmaceutics and Pharmacokinetics, pp. 529–535, Vol. II, Experimental Pharmacokinetics, 24–27 April, Salamanca, Spain, 1984
Giudicelli J, Chauvin M, Thuillez C, Richer C, Bianchetti G, et al. Beta-adrenoceptor blocking effects and pharmacokinetics of betaxolol (SL 75212) in man. British Journal of Clinical Pharmacology 10: 41–49, 1980
Goldberg I. Betaxolol. Australian and New Zealand Journal of Ophthalmology 17: 9–13, 1989
Harris LS, Greenstein SH, Bloom AF. Respiratory difficulties with betaxolol. American Journal of Ophthalmology 102: 274–275, 1986
Hermann P, Thenot J, Warrington S, Ganansia J, Morselli P. Metabolism of betaxolol in man. Abstract no. 272. 8th European Workshop on Drug Metabolism, Sart Tilman, Belgium, September 5–9, 1982
Hernandez y Hernandez H, Cervantes R, Frati A. Cardiovascular effects of topical glaucoma therapies in normal subjects. Journal of Toxicology — Cutaneous and Ocular Toxicology 2: 99–106, 1983
Herschman Z, Kaufman B. Complications arising from the use of ophthalmologic medications in an intensive care unit patient. New York State Journal of Medicine 89: 537–538, 1989
Hugues FC. Clinical studies of systemic effects of topical beta blockers. International Ophthalmology Clinics 29 (Suppl.): S19–S20, 1989
Kitazawa Y, Azuma I, Araie M. Clinical evaluation of betaxolol hydrochloride in the treatment of primary open angle glaucoma and ocular hypertension: multicentre double-masked study in comparison with timolol. Rinsho Hyoka 17: 243–274, 1989
Le Jeunne C, Bringer L, Mondjee-Tahura Z, Munera Y, Hugues FC. Effets cardio-vasculaires des collyres au timolol, au cartéolol, au métipranolol, au bétaxolol chez le sujet âgé. Therapie 43: 89–92, 1988
Le Jeunne C, Munera Y, Hugues FC. Systemic effects of 3 beta-blocker eyedrops: comparison in healthy volunteers of gb1 and β2 adrenoceptor inhibition. Clinical Pharmacology and Therapeutics, in press, 1990
Lesar TS. Comparison of ophthalmic β-blocking agents. Clinical Pharmacy 6: 451–463, 1987
Levy NS, Boone LR. Effects of 0.25% betaxolol vs placebo. Glaucoma 5: 230, 1983
Levy NS, Boone L, Ellis E. A controlled comparison of betaxolol and timolol with long-term evaluation of safety and efficacy. Glaucoma 7: 54–62, 1985
Liu GS, Trope GE, Basu PK. A comparison of topical betoptic and timoptic on corneal re-epithelialization in rabbits. Journal of Toxicology — Cutaneous and Ocular Toxicology 6(4): 335–343, 1987
Liu GS, Trope GE, Basu PK. Ultrastructural effects of topical Betoptic, Betagan, and Timoptic on the rabbit corneal endothelium. Journal of Ocular Pharmacology 5: 329–342, 1989
Lynch MG Whitson JT, Brown RH, Nguyen H, Drake MM. Topical β-blocker therapy and central nervous system side effects, a preliminary study comparing betaxolol and timolol. Archives of Ophthalmology 106: 908–911, 1988
Manoury P. Betaxolol: chemistry and biological profile in relation to its physicochemical properties. In Morselli et al. (Eds) LERS Monograph Series, Vol. 1, pp. 13–19, Raven Press, New York, 1983
Mekki QA, Davies IB, Sinclair AJ, Turner P. Effect ofβ2 -selective adrenoceptor blockers on intraocular pressure in man. Abstract. British Journal of Clinical Pharmacology 21: 596P-597P, 1985
Merte HI, Schnarr KD. Ophthalmic betaxolol: a twelve-week study in glaucoma patients. New Trends in Ophthalmology 2: 98–108, 1987
Morselli PL, Thiercelin JF, Padovani P, Bianchetti G, Fries D, et al. Comparative pharmacokinetics of several beta-blockers in renal and hepatic insufficiency. In Morselli et al. (Eds) LERS Monograph Series, Vol. 1, pp. 233–241, Raven Press, New York, 1983
Nelson WL, Kuritsky JN. Early postmarketing surveillance of betaxolol hydrochloride, September 1985–September 1986. American Journal of Ophthalmology 103: 592, 1987
Ofner S, Smith TJ. Betaxolol in chronic obstructive pulmonary disease. Journal of Ocular Pharmacology 3: 171–176, 1987
Orlando RG. Clinical depression associated with betaxolol. Correspondence. American Journal of Ophthalmology 102: 275, 1986
Palminteri R, Kaik G. Time course of the bronchial response to salbutamol after placebo, betaxolol and propranolol. European Journal of Clinical Pharmacology 24: 741–745, 1983
Pecori-Giraldi J, Collini S, Planner-Terzaghi A, Arrico L, Grechi G. Timolol, Betaxolol und Befunolol in der Glaukombehandlung. Untersuchung über die bronchopulmonalen Effekte. Fortschritte der Ophthalmologie 85: 235–238, 1988
Pillunat L, Stodtmeister R. Effect of different antiglaucomatous drugs on ocular perfusion pressures. Journal of Ocular Pharmacology 4: 231–242, 1988
Polansky JR, Alvarado JA. Isolation and evaluation of target cells in glaucoma research: hormone receptors and drug responses. Current Eye Research 4: 267–279, 1985
Radius RL. Use of betaxolol in the reduction of elevated intraocular pressure. Archives of Ophthalmology 101: 898–900, 1983
Reiss GR, Brubaker RF. The mechanism of betaxolol, a new ocular hypotensive agent. Ophthalmology 90: 1369–1372, 1983
Riddell JG, Shanks RG. Comparative effects of betaxolol, propranolol and atenolol on isoprenaline-induced responses in man. British Journal of Clinical Pharmacology 19: 138P, 1985
Robinson JC, Kaufman PL. Effects and interactions of epinephrine, norepinephrine, timolol and betaxolol on outflow facility in the cynomolgus monkey. American Journal of Ophthalmology 109: 189–194, 1990
Roholt PC. Betaxolol and restrictive airway disease. Archives of Ophthalmology 105: 1172, 1987
Ryan M, Jain AK, Ryan JR, McMahon FG, Richards J. Relative ocular tolerance of ophthalmic solutions of timolol and betaxolol in normal volunteers. Clinical Pharmacology and Therapeutics 41: 193, 1987
Scheuker HI, Tablouski ME, Podos SM, Linder L. Fluoropho-tometric study of epinephrine and timolol in human subjects. Archives of Ophthalmology 99: 1212, 1981
Schoene RB, Abuan T, Ward RL, Beasley CH. Effects of topical betaxolol, timolol and placebo on pulmonary function in asthmatic bronchitis. American Journal of Ophthalmology 97: 86–92, 1984
Shanks RG. Clinical pharmacology of beta-adrenoceptor blocking drugs. In Morselli et al. (Eds) LERS Monograph Series, Vol. 1, pp. 73–88, Raven Press, New York, 1983
Smith JP, Weeks RH, Newland EF, Ward RL. Betaxolol and acetazolamide, combined ocular hypotensive effect. Archives of Ophthalmology 102: 1794–1795, 1984
Stewart RH, Kimbrough RL, Ward RL. Betaxolol vs timolol, a six-month double-blind comparison. Archives of Ophthalmology 104: 46–48, 1986
Thiercelin J, Bianchetti G, Larribaud J, Ganansia J, Deves C, et al. Effects of meal and its composition on the bioavailability of betaxolol administered orally to healthy subjects. In Debrey (Ed.) World review of nutrition and dietetics, Vol. 33, pp. 183–186, Karger, Basel, 1984
Thomas JV, Epstein DL. Timolol and epinephrine in primary open angle glaucoma. Transient additive effect. Archives of Ophthalmology 99: 91, 1981
Trope GE, Liu GS, Basu PK. Toxic effects of topically administered betagan, betoptic and timoptic on regenerating corneal epithelium. Journal of Ocular Pharmacology 4: 359–366, 1988
Van Buskirk EM. In vivo methacrylate casting technique for studies of ocular vasculature. International Ophthalmology Clinics 29 (Suppl.): S12–S13, 1989
Van Buskirk EM, Weinreb RN, Berry DP, Lustgarten JS, Podos SM. Betaxolol in patients with glaucoma and asthma. American Journal of Ophthalmology 101: 531–534, 1986
Vogel R, Tipping R, Kulaga SF, Clineschmidt CM, The Timolol-Betaxolol Study Group. Changing therapy from timolol to betaxolol. Effect on intraocular pressure in selected patients with glaucoma. Archives of Ophthalmology 107: 1303–1307, 1989
Vukich JA, Leef DL, Allen RC. Betaxolol in patients with coexistent chronic open angle glaucoma and pulmonary disease. Investigative Ophthalmology and Visual Science 26 (Suppl): 227, 1986
Warrington S, Turner P, Kilborn J, Bianchetti G, Morselli P. Blood concentrations and pharmacodynamic effects of betaxolol (SL 75212) a new beta adrenoceptor antagonist after oral and intravenous administration. British Journal of Clinical Pharmacology 10: 449–452, 1980
Watanabe K, Chiou GCY. Mechanism of action of timolol to lower the intraocular pressure in rabbits. Ophthalmic Research 15: 160–167, 1983
Wax MB, Molinoff PB. Distribution and properties of β-adrenergic receptors in human iris-ciliary body. Investigative Ophthalmology and Visual Science 28: 420–430, 1987
Wax MB, Molinoff PB, Alvarado J, Polansky J. Characterization of β-adrenergic receptors in cultured human trabecular cells and in human trabecular meshwork. Investigative Ophthalmology and Visual Science 30: 51, 1989
Weinreb RN, Ritch R, Kushner FH. Effect of adding betaxolol to dipivefrin therapy. American Journal of Ophthalmology 101: 196–198, 1986
Weinreb RN, van Buskirk EM, Cherniack R, Drake MM. Long-term betaxolol therapy in glaucoma patients with pulmonary disease. American Journal of Ophthalmology 106: 162–167, 1988
Wright S, Edgar DF, Stewart-Jones JH, Turner P. Comparison of topical betaxolol, carteolol, metipranolol and saline on intraocular pressure in normal volunteers. British Journal of Clinical Pharmacology 27: 696P-697P, 1988
Zabel RW, MacDonald IM. Sinus arrest associated with betaxolol ophthalmic drops. American Journal of Ophthalmology 104: 431, 1987
Author information
Authors and Affiliations
Additional information
Various sections of the manuscript reviewed by: J.M. Atkins, Division of Cardiology, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas, USA; H. Bleckmann, Department of Ophthalmology, Akademisches Lehrkrankenhaus der Freien Universität Berlin, West Germany; B. Brogliatti, Department of Ophthalmology, University of Turin, Turin, Italy; A.M.V. Brooks, Glaucoma Investigation and Research Unit, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia; J.B. Clark, Glaucoma Investigation and Research Unit, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia; K. Dickstein, Cardiology Department, Central Hospital in Rogaland, Stavangen, Norway; W.E. Gillies, Glaucoma Investigation and Research Unit, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia; F.C. Hugues, Laboratorie de Thérapeutique Appliquée, Service de Médecine Interne, Hôpital Laennec, Paris, France; IH. Leopold, Department of Ophthalmology, University of California, Irvine, California, USA; J. Pecori-Giraldi, Department of Ophthalmology, University of Rome, Rome, Italy; C.I. Phillips, Ophthalmology Unit, University Department of Surgery, University of Edinburgh, Edinburgh, Scotland; K. Segawa, Department of Ophthalmology, Shinshu University School of Medicine, Nagano-ken, Japan; P. Turner, Department of Clinical Pharmacology, St Bartholomew’s Hospital Medical College, University of London, London, England.
Rights and permissions
About this article
Cite this article
Buckley, M.MT., Goa, K.L. & Clissold, S.P. Ocular Betaxolol. Drugs 40, 75–90 (1990). https://doi.org/10.2165/00003495-199040010-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199040010-00005